CANGENE ANNOUNCES FISCAL 2005 FINANCIAL RESULTS

Cangene Corporation today reports financial results for the year ended July 31, 2005. Revenues for the year were $102.7 million, down $54.2 million or 35% from fiscal 2004. The decrease relates primarily to the completion of the Vaccinia immune globulin (VIG) contract with the U.S. government, which was ongoing in 2004 and generated $42.3 million in revenue last year compared with $3.5 million in total VIG sales in 2005.

Canada NewsWire (http://www.newswire.ca/en/releases/archive/October2005/19/c3460.html)